New Biomarker, Subgroup Analyses of Phase 3 NefIgArd Trial for Budesonide

Positive findings from NefIgArd demonstrated budesonide’s ability to modulate the intestinal immune network responsible for IgA production.

Related Keywords

Tokyo ,Japan ,Jonathan Barratt ,Richard Phillipson ,International Symposium On Iga Nephropathy Iigann Tokyo ,Drug Administration ,International Symposium On Ig ,International Symposium On Iga Nephropathy ,George Clinical ,Calliditas Therapeutics ,Cc Motif Chemokine Ligand ,International Symposium ,Chief Medical Officer ,Prescription Drug User Fee Act ,Iga Nephropathy ,Mayer Professor ,Renal Medicine ,Calliditas Presents Data ,Nefigard Phase ,Calliditas Therapeutics Accelerated Approval ,Reduce Proteinuria ,Patients With Primary Iga ,Igard Trial Evaluating Nefecon ,Immunoglobulina Nephropathy ,Wigan ,Nefigard ,Budesonide ,Nefecon ,Tarpeyo ,